chip-clonal-hematopoiesis-agent

name	chip-clonal-hematopoiesis-agent
description	AI-powered clonal hematopoiesis of indeterminate potential (CHIP) detection, risk stratification, and cardiovascular/malignancy risk prediction using genomic and clinical data.

CHIP Clonal Hematopoiesis Agent

The CHIP Clonal Hematopoiesis Agent provides comprehensive detection and risk stratification of clonal hematopoiesis of indeterminate potential (CHIP). It identifies clonal mutations in blood cells, assesses risk of progression to myeloid malignancy, and predicts cardiovascular disease risk, integrating with the CHIC machine learning framework for CBC-based screening.

When to Use This Skill

• When detecting CHIP mutations from blood sequencing data.
• For stratifying risk of progression to MDS/AML.
• To assess CHIP-associated cardiovascular disease risk.
• When filtering CHIP variants from tumor liquid biopsy.
• For population-level CHIP screening and research.

Core Capabilities

1. CHIP Detection: Identify clonal mutations with VAF >2%.

2. Risk Stratification: Predict myeloid malignancy progression risk.

3. CVD Risk Assessment: Estimate cardiovascular disease risk.

4. CCUS Classification: Distinguish CHIP from CCUS/MDS.

5. Clone Size Tracking: Monitor clonal evolution over time.

6. ctDNA Filtering: Remove CHIP from tumor ctDNA analysis.

CHIP-Associated Genes

Gene	Frequency	Malignancy Risk	CVD Risk
DNMT3A	50%	Moderate	Elevated
TET2	20%	Moderate	Elevated (inflammatory)
ASXL1	10%	High	Moderate
JAK2	5%	High (MPN)	Elevated (thrombosis)
TP53	5%	Very High	Low
SF3B1	3%	Moderate-High	Low
SRSF2	3%	High	Low
PPM1D	2%	Moderate	Therapy-related
CBL	2%	High	Moderate
IDH1/2	2%	Moderate-High	Low

Risk Categories

Category	Criteria	Annual AML Risk
Low-Risk CHIP	DNMT3A/TET2, VAF <10%	<0.5%
Intermediate CHIP	DNMT3A/TET2, VAF >10%	0.5-1%
High-Risk CHIP	ASXL1, TP53, splicing	1-3%
CCUS	CHIP + cytopenia	3-10%
Pre-MDS	High-risk mutations + dysplasia	>10%

Workflow

1. Input: Blood sequencing (WES/panel), CBC data, clinical history.

2. Variant Detection: Call somatic variants with VAF filtering.

3. CHIP Classification: Identify CHIP-defining mutations.

4. Risk Scoring: Calculate malignancy and CVD risk scores.

5. Longitudinal Analysis: Track clone dynamics if serial samples.

6. Clinical Integration: Generate management recommendations.

7. Output: CHIP status, risk scores, monitoring plan.

Example Usage

User: "Analyze this patient's blood sequencing for CHIP and calculate their risk of progression and cardiovascular events."

Agent Action:

python3 Skills/Hematology/CHIP_Clonal_Hematopoiesis_Agent/chip_analysis.py \
    --variants blood_variants.vcf \
    --cbc_data patient_cbc.csv \
    --clinical_data patient_demographics.json \
    --vaf_threshold 0.02 \
    --age 65 \
    --calculate_cvd_risk true \
    --output chip_analysis/

CHRS Risk Score (Clonal Hematopoiesis Risk Score)

Factor	Points	Notes
High-risk mutation	+2	SRSF2, SF3B1, ZRSR2, IDH1/2, FLT3, RUNX1, JAK2
Single DNMT3A mutation	-1	Lower risk
≥2 mutations	+1	Increased burden
VAF ≥20%	+1	Large clone
CCUS (vs CHIP)	+2	Cytopenia present
RDW ≥15%	+1	Blood count abnormality
MCV ≥100 fL	+1	Macrocytosis
Age ≥65	+1	Age-related risk

Output Components

Output	Description	Format
CHIP Status	Present/Absent, genes involved	.json
Mutation Details	VAF, gene, protein change	.csv
Malignancy Risk	5-year AML/MDS probability	.json
CVD Risk	Cardiovascular risk score	.json
CHRS Score	Clonal hematopoiesis risk score	.json
Recommendations	Clinical management	.md
Monitoring Plan	Follow-up schedule	.json

AI/ML Components

CHIC Framework:

• Machine learning from CBC indices
• Identifies high-risk CHIP without sequencing
• Reduces "number needed to sequence"

Risk Prediction:

• Cox proportional hazards for progression
• Random survival forests
• Deep learning survival models

CVD Risk Integration:

• Framingham score adjustment
• CHIP-specific hazard ratios
• Inflammatory biomarker integration

Cardiovascular Risk

CHIP Gene	CVD Hazard Ratio	Mechanism
TET2	1.9	IL-6, inflammasome
DNMT3A	1.7	Inflammation
JAK2	2.6	Thrombosis, platelet activation
ASXL1	2.0	Inflammation
Overall CHIP	1.5-2.0	Multiple pathways

Clinical Management Guidelines

CHIP Category	Monitoring	Intervention
Low-risk	Annual CBC	None
Intermediate	CBC q6 months	CVD optimization
High-risk	CBC q3-6 months, consider BMB	Hematology referral
CCUS	BMB, q3 month CBC	Active surveillance

Prerequisites

• Python 3.10+
• Variant callers (Mutect2, VarScan)
• ANNOVAR/VEP for annotation
• lifelines, scikit-survival
• CHIC model weights

Related Skills

• MPN_Progression_Monitor_Agent - MPN monitoring
• CHIC_ML_Framework_Agent - CBC-based screening
• MDS_Classification_Agent - MDS diagnosis
• Bone_Marrow_AI_Agent - Morphology analysis

CHIP vs ctDNA Filtering

Feature	CHIP	Tumor ctDNA
VAF Stability	Stable over time	Changes with disease
Genes	DNMT3A, TET2, ASXL1	Tumor drivers
Age Association	Increases with age	Independent
Multiple Samples	Consistent	Variable

Special Considerations

1. VAF Threshold: Use 2% for CHIP definition
2. Germline Filtering: Exclude germline variants
3. Age Context: Prevalence increases with age
4. Therapy History: Consider treatment-related clones
5. Serial Monitoring: Track clone dynamics

Population Prevalence

Age Group	CHIP Prevalence	High-Risk CHIP
40-49	~2%	<0.5%
50-59	~5%	~1%
60-69	~10%	~2%
70-79	~15%	~4%
80+	~20%	~5%

Therapeutic Implications

Scenario	CHIP Impact	Consideration
CAR-T Therapy	May affect outcomes	Monitor clones
Stem Cell Transplant	Donor CHIP matters	Screen donors
Chemotherapy	May expand clones	Monitor post-treatment
Cardiovascular	Increased risk	Aggressive prevention

Author

AI Group - Biomedical AI Platform